ChemoCentryx, Inc.
ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel medicines that selectively block key chemokine or chemoattractant receptors to address high unmet medical needs in inflammatory and autoimmune diseases. The company’s lead investigational candidate avacopan (CCX168), an oral complement 5a receptor inhibitor (C5aR), is in a Phase III clinical trial for the treatment of ANCA-associated vasculitis, and in Phase II trials for complement 3 glomerulopathy and hidradenitis suppurativa. The company’s orally administered CCR2 inhibitor, CCX140, is in Phase II trials for focal segmental glomerulosclerosis